Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.50 |
| ▸ | HTR3B | O95264 | 2/20 | 0.50 |
| ▸ | HTR3A | P46098 | 2/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168350 | 0.82 | ALDH1A1 (0.54) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL30313129 | 0.82 | ALDH1A1 (0.54) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL1457686 | 0.81 | CA12 (0.52) | ALDH1A1MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30940602 | 0.81 | CA12 (0.52) | ALDH1A1MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1020510 | 0.80 | ACHE (0.50) | ALDH1A1MAPTCYP3A4MAPK1APLNR | |
| SCHEMBL11415006 | 0.80 | APLNR (0.41) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL22469823 | 0.79 | ALPL (0.34) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL6113969 | 0.79 | APLNR (0.40) | ALDH1A1CYP3A4MAPK1APLNRMEN1 | |
| SCHEMBL6117909 | 0.79 | APLNR (0.40) | ALDH1A1CYP3A4APLNRLMNAKDM4E | |
| SCHEMBL2142308 | 0.77 | APLNR (0.39) | ALDH1A1MAPTCYP1A2CYP3A4APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111138358-B | USP8 inhibitor and preparation method and application thereof | 中国药科大学 | 2023-04-18 | — | — | CN | disclosed |
| CN-111138358-A | USP8 inhibitor and preparation method and application thereof | 中国药科大学 | 2020-05-12 | — | — | CN | disclosed |
| EP-3296309-B1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | UNIV GENT (BE) | 2019-08-07 | — | — | EP | disclosed |
| EP-3296309-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | Universiteit Gent (BE) | 2018-03-21 | — | — | EP | disclosed |
| EP-2877480-B1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | UNIV GENT (BE) | 2017-09-06 | — | — | EP | disclosed |
| US-9321796-B2 | Galactopyranosyl derivatives useful as medicaments | UNIVERSITEIT GENT (BE) | 2016-04-26 | — | — | US | disclosed |
| US-20150210728-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | AMBICION CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| EP-2877480-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | Universiteit van Gent (BE) | 2015-06-03 | — | — | EP | disclosed |
| EP-1888596-B1 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-8865753-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-10-21 | — | — | US | disclosed |
| EP-0876354-A1 | 2-(SUBSTITUTED SULFANYL)-3,5-DIHYDRO-IMIDAZOL-4-ONE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-11-11 | — | — | EP | disclosed |
| US-5783707-A | ANTICHOLESTEROL AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-07-21 | — | — | US | disclosed |
| WO-1997019931-A1 | 2-(SUBSTITUTED SULFANYL)-3,5-DIHYDRO-IMIDAZOL-4-ONE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-06-05 | — | — | WO | disclosed |
| WO-1997019932-A1 | 2-THIOXO-IMIDAZOLIDIN-4-ONE DERIVATIVES AND THEIR USE FOR INCREASING HDL CHOLESTEROL CONCENTRATION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-06-05 | — | — | WO | disclosed |
| US-5599829-A | FOR INCREASED HIGH DENSITY LIPOPROTEIN LEVELS IN BLOOD | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-02-04 | — | — | US | disclosed |
| US-5554607-A | INCREASING HDL CHOLESTEROL | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-09-10 | — | — | US | disclosed |
| US-5393883-A | Ribonucleotide reductase inhibitors | BURROUGHS WELLCOME CO. (US) | 1995-02-28 | — | — | US | disclosed |
| US-5175165-A | Acyclovir and a thiocarbonohydrazone ribonucleotide reductase inhibitor for treatment of herpes virus | BURROUGHS WELLCOME CO. (US) | 1992-12-29 | — | — | US | disclosed |
| EP-0349243-B1 | ANTIVIRAL COMBINATIONS AND COMPOUNDS THEREFOR | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-04-01 | — | — | EP | disclosed |
| EP-0349243-A2 | Antiviral combinations and compounds therefor | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210728-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | B3GAT3, GALR3, ST6GAL1 | HTR3E 2019/4885HTR3B 2158/4885HTR3A 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.